A common antibiotic may help Crohn's patients get more out of biologic therapy
NCT ID NCT05599347
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether a short course of azithromycin, taken before starting anti-TNF therapy, can reduce the body's tendency to develop antibodies against the biologic drug. Antibodies can make the treatment less effective over time. The study enrolls adults with Crohn's disease who are about to begin anti-TNF therapy and compares azithromycin to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azithromycin pill
- What this could lead to
- If it works, this could point toward a simple way to make anti-TNF therapy more effective and durable for people with Crohn's disease.
- What could go wrong
- This is a mid-stage trial, so the approach may not prove effective. Azithromycin can cause side effects like gastrointestinal upset or antibiotic resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOLOGICAL SUBSTANCE; ADVERSE EFFECT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bnei Zion
RECRUITINGHaifa, Israel
-
Carmel Medical Center
RECRUITINGHaifa, Israel
-
Hadassah Medical Center
RECRUITINGJerusalem, Israel
-
Rabin Medical Center
RECRUITINGPetah Tikva, Israel
-
Rambam Health Care Campus
RECRUITINGHaifa, Haifa District, Israel
-
Shaare Zedek
RECRUITINGJerusalem, Israel
-
Soroka University Medical Center
RECRUITINGBeersheba, Israel
-
Wolfson Medical Center
RECRUITINGHolon, Israel
-
Zvulun
RECRUITINGKiryat Bialik, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.